[Click eStock] "Adbiotech, Exclusive Supplier of Microbial Agents... Expected Performance Growth"

Hana Securities forecasted on the 25th that the performance growth of Adbiotech, which exclusively supplies microbial agents, will be steep. No investment opinion or target price was provided.

Adbiotech, established in 2000, is a next-generation immune antibody-based biopharmaceutical company. It applies immune antibody technology to produce and sell products for livestock, aquaculture, and human use. The company owns its own manufacturing and quality control facilities for animal pharmaceuticals, including fermenters, centrifuges, freeze dryers, and mixers. Its representative technologies include immune egg yolk antibodies and nanobody antibody platforms.

Choi Jae-ho, a researcher at Hana Securities, stated, "Attention should be paid to Adbiotech's new growth engine: microbial agents for food waste treatment," adding, "The domestic food waste treatment device market size was approximately 980 billion KRW as of last year, with a penetration rate of only about 5%, indicating ample room for growth."

Researcher Choi continued, "Within the rapidly growing food waste treatment device market, the microbial fermentation method should be noted. Starting this year, Adbiotech is expected to exclusively supply microbial agents for food waste treatment to the world's top home appliance company and a leading domestic rental company," and added, "Currently, small and medium-sized enterprises hold the number one market share for microbial food waste treatment devices, but with the entry of large corporations into the rental service and built-in market, a shift in the market landscape is anticipated." He further stated, "Accordingly, the performance growth of Adbiotech, which exclusively supplies microbial agents, is expected to be steep."

This content was produced with the assistance of AI translation services.